Future Challenges And Predictions For CGT Patient-Focused Solutions

An increasing number of cell and gene therapies are advancing through clinical trials, with some reaching commercialization. As these products grow to become more diverse and complex, more supporting partners and more steps are needed to deliver these therapies safely to patients. Personalized medicines demand a robust chain of identity and just this lone factor adds complexity to the delivery of these therapies. Obstacles relating to limited treatment networks and patient access also persist in the cell and gene therapy industry, making it critical to remove transportation barriers for patients and caregivers with minimal out-of-pocket expenses.

Transparent collaboration and communication are going to be more critical than ever when it comes to offering a high level of patient support. Delivering and scaling up these advanced therapeutics will require biopharma suppliers to break down silos to ensure seamless, accurate, secure, and timely information transfer. Leveraging innovative digital technologies to predict, model, and analyze data and scenarios will help to enhance resource allocation, improve patient experience, reduce time to treatment, and drive cost and safety efficiencies.

Dale Hanna, Director, Cell and Gene Therapy (CGT) at AmerisourceBergen, partners with Dr. Matthew Lakelin, Vice President, Scientific Affairs and Product Development at TrakCel, for a Q&A session. Together, they explore upcoming challenges and predictions for patient-centric solutions within the CGT field.